Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2018 1
2019 2
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis.
Dhillon AK, Kremer AE, Kummen M, Boberg KM, Elferink RPO, Karlsen TH, Beuers U, Vesterhus M, Hov JR. Dhillon AK, et al. Sci Rep. 2019 Jun 11;9(1):8450. doi: 10.1038/s41598-019-44762-7. Sci Rep. 2019. PMID: 31186435 Free PMC article.

Kaplan-Meier survival analyses showed a strong association between increasing autotaxin activity and shorter liver transplant-free survival (discovery panel: P < 0.001, validation panel: P = 0.001). ...In conclusion, increased serum autotaxin

Kaplan-Meier survival analyses showed a strong association between increasing autotaxin activity and shorter liver transpla
Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.
Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygård S, Godang K, Andersen IM, Naess S, Thorburn D, Saffioti F, Vatn M, Gilja OH, Lund-Johansen F, Syversveen T, Brabrand K, Parés A, Ponsioen CY, Pinzani M, Färkkilä M, Moum B, Ueland T, Røsjø H, Rosenberg W, Boberg KM, Karlsen TH. Vesterhus M, et al. Hepatology. 2015 Jul;62(1):188-97. doi: 10.1002/hep.27825. Epub 2015 Apr 28. Hepatology. 2015. PMID: 25833813
There is a need to determine biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis (PSC). We evaluated the prognostic utility of the enhanced liver fibrosis (ELF) score in Norwegian PSC patients. .. …
There is a need to determine biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis (PS …
Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
Bossen L, Vesterhus M, Hov JR, Färkkilä M, Rosenberg WM, Møller HJ, Boberg KM, Karlsen TH, Grønbæk H. Bossen L, et al. Clin Transl Gastroenterol. 2021 Mar 1;12(3):e00315. doi: 10.14309/ctg.0000000000000315. Clin Transl Gastroenterol. 2021. PMID: 33646203 Free PMC article.
INTRODUCTION: Primary sclerosing cholangitis (PSC) is a progressive liver disease characterized by bile duct inflammation and fibrosis. ...In both cohorts, sCD163 and sMR levels raised with increasing disease severity (liver enzymes, Mayo …
INTRODUCTION: Primary sclerosing cholangitis (PSC) is a progressive liver disease characterized by bile duct inf …
Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis.
Mazhar A, Russo MW. Mazhar A, et al. Aliment Pharmacol Ther. 2021 Apr;53(7):774-783. doi: 10.1111/apt.16296. Epub 2021 Feb 19. Aliment Pharmacol Ther. 2021. PMID: 33608929 Review.
BACKGROUND: Several prognostic tests for primary sclerosing cholangitis (PSC) have been developed, including biochemical models, elastography and magnetic resonance imaging scores. ...Promising prognostic models include the enhanced liver
BACKGROUND: Several prognostic tests for primary sclerosing cholangitis (PSC) have been developed, including biochemica …
Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis.
Schmeltzer PA, Russo MW. Schmeltzer PA, et al. J Clin Med. 2021 Sep 28;10(19):4476. doi: 10.3390/jcm10194476. J Clin Med. 2021. PMID: 34640494 Free PMC article. Review.
Outcomes included transplant-free survival or composite clinical outcomes. The rMRS was better than the Amsterdam-Oxford model for predicting 1-year transplant-free survival, c-statistics 0.75 and 0.70, respectively. ...An enhan
Outcomes included transplant-free survival or composite clinical outcomes. The rMRS was better than the Amsterdam-Oxfor …
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U. Hirschfield GM, et al. J Hepatol. 2019 Mar;70(3):483-493. doi: 10.1016/j.jhep.2018.10.035. Epub 2018 Nov 9. J Hepatol. 2019. PMID: 30414864 Free article. Clinical Trial.
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic liver disease devoid of effective medical intervention. ...Importantly, fibrosis biomarkers that predict transplant
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic …
Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
Vesterhus M, Holm A, Hov JR, Nygård S, Schrumpf E, Melum E, Thorbjørnsen LW, Paulsen V, Lundin K, Dale I, Gilja OH, Zweers SJLB, Vatn M, Schaap FG, Jansen PLM, Ueland T, Røsjø H, Moum B, Ponsioen CY, Boberg KM, Färkkilä M, Karlsen TH, Lund-Johansen F. Vesterhus M, et al. J Hepatol. 2017 Jun;66(6):1214-1222. doi: 10.1016/j.jhep.2017.01.019. Epub 2017 Feb 2. J Hepatol. 2017. PMID: 28161472
BACKGROUND & AIMS: Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and the development of therapy. ...However, the Enhanced Liver Fibrosis (ELF) test and Mayo risk score proved to be …
BACKGROUND & AIMS: Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and …